Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $53.89 USD
Change Today -1.00 / -1.82%
Volume 135.7K
As of 6:40 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy's Laboratories Wins GBP 200,128 Multiple Awardees Contract for Supplying Aripiprazole Medicines

Dr. Reddy's Laboratories, Cambridge, won a GBP 200,128 (excluding VAT) multiple awardees contract award from The Common Services Agency (more commonly known as NHS National Services Scotland) ('the Authority') for the supply of Aripiprazole medicines (Tablets) (Contract Award Notice No.: 2015/S 104-188988; Lot No.: 1).

Dr Reddy's Laboratories Limited Announces the Availability of Somazina

Dr Reddy's Laboratories Limited has announced the availability of Somazina, which is indicated for the management of stroke, in India. Somazina is the innovator brand of Citicoline. Dr. Reddy's has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India. This is an important product in the management of stroke and has been used for the treatment of post-stroke patients around the world. Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.

Dr Reddy's Laboratories Limited and Astrazeneca Pharma India Limited Enter Distribution Agreement

Dr. Reddy's Laboratories Ltd. and AstraZeneca Pharma India Limited entered into a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination with metformin, in Type 2 Diabetes. Both Riax and Riax M are trademarks of the AstaZenca Group.

Dr. Reddy's Laboratories Ltd. Wins GBP 230 Million Multiple Awardees Contract for Supplying Generic Pharmaceuticals

Dr. Reddy's Laboratories Ltd. has won a GBP 230 million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic pharmaceuticals.

Dr. Reddy's Laboratories Ltd. - Analyst/Investor Day

Dr. Reddy's Laboratories Ltd. - Analyst/Investor Day


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $53.89 USD -1.00

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,403 INR -28.30
Cadila Healthcare Ltd 1,716 INR -25.60
Croda International PLC 2,777 GBp -59.00
Lonza Group AG SFr.124.80 CHF -2.50
Symrise AG €55.82 EUR -1.67
View Industry Companies

Industry Analysis


Industry Average

Valuation RDY Industry Range
Price/Earnings 26.8x
Price/Sales 4.0x
Price/Book 5.3x
Price/Cash Flow 26.7x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at